HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Aprea Therapeutics (NASDAQ:APRE) and maintained a $20 price target.
September 13, 2023 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aprea Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $20.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Aprea Therapeutics. This could potentially attract investors, leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100